Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Novartis Pharma AG: Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Among 26 ResMed-supported abstracts, these were the highlights: New findings show positive airway pressure therapy reduced risks of death and hospitalization for patients with obstructive sleep.
Ophthalmology registry data show increased macular fluid volume after initial treatment are associated with increased numbers of injections in nAMD treatment.
Transformation in COPD care is underway as Speak Up for COPD unites policymakers, healthcare professionals, patients, caregivers, NGOs, and pharmaceutical industry to help make COPD a public health priority.